Background:
• Alterations in the RAS pathway are linked to tumorigenesis
• RAS alterations are currently under-studied in breast cancer (BC) compared to other solid tumors
• HRAS can be indirectly targeted with tipifarnib, a farnesyltransferase inhibitor
• We aimed to characterize the molecular characteristics and understand clinical outcomes of BC with HRAS mutations (HRASmut)